Evidence map›Paper›PMID 39962137›Full record

ArticleCommunications medicine2025

Early cardio-oncology intervention in thoracic radiotherapy: prospective single-arm pilot study.

Samuel C Zhang, Jordan O Gasho, Celeste Eno, Katrina D Silos, Felicity Pendergast, Wenjuan Zhang, Eric Vail, Mitchell Kamrava, Behrooz Hakimian, Amin Mirhadi and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Samuel C ZhangDepartment of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Jordan O GashoDepartment of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Celeste EnoDepartment of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-3857-9519
Katrina D SilosDepartment of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Felicity PendergastCancer Clinical Trials Office, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Wenjuan ZhangDepartment of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Eric VailDepartment of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-6578-178X
Mitchell KamravaDepartment of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Behrooz HakimianDepartment of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Amin MirhadiDepartment of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Raymond H MakDepartment of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-8754-0565
Andriana P NikolovaDepartment of Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Katelyn M AtkinsDepartment of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. katelyn.atkins@cshs.org.ORCID http://orcid.org/0000-0002-3165-4803

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhile there is increasing recognition of the morbidity of cardiovascular disease in cancer survivors, including accelerated atherosclerosis following thoracic radiotherapy, patients are frequently under-optimized for cardiovascular risk.

methodsIn this prospective single-arm cohort pilot study, patients were treated with high-dose thoracic radiotherapy and had early consultation with cardio-oncology. Twenty patients were enrolled. The primary endpoint was adherence to cardio-oncology consultation. Secondary endpoints were cardiovascular medication intervention rate and patient-reported intervention perspectives. Clonal hematopoiesis of indeterminate potential, a major cardiovascular risk marker enriched in patients with cancer and induced by radiation exposure, was measured as an exploratory endpoint.

resultsThe cohort median age is 71 years. Most patients are female (13/20), have primary lung or esophageal carcinoma (16/20), and 7/20 have pre-existing cardiovascular disease. We show that cardio-oncology consultation adherence is high (19/20) and results in cardiovascular medication optimization changes in most patients (12/19), most commonly to initiate or intensify statin therapy (8/12). 8/12 patients with a primary cardiologist prior to enrollment have medication changes recommended. Most (12/17) participants are glad to learn about their heart health during cancer treatment. Clonal hematopoiesis is detectable prior to treatment in 8/20 patients and three develop new variants after treatment (1/3 de novo).

conclusionsWe observe that early cardio-oncology consultation is feasible, leads to cardiovascular medication optimization in the majority (>60%) of participants, most commonly to initiate or intensify statin therapy. New clonal hematopoiesis variants are detectable early after radiotherapy and the impact on post-treatment cardiovascular risk is worthy of further study.

Identifiers

PMID39962137
PMCPMC11833047

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.